{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T18:20:14Z","timestamp":1774376414598,"version":"3.50.1"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:p>Primary sinonasal diffuse large B-cell lymphoma (PSDLBCL) is a rare aggressive lymphoma. Recently, genetic classification using Next Generation Sequencing (NGS) demonstrated that PSDLBCL largely consists of the MCD genotype, which has a poor prognosis mainly driven by <jats:italic toggle=\"yes\">MYD88<\/jats:italic> L265P and <jats:italic toggle=\"yes\">CD79B<\/jats:italic> gene abnormalities. This study investigated the prevalence and clinicopathological significance of <jats:italic toggle=\"yes\">MYD88<\/jats:italic> L265P and <jats:italic toggle=\"yes\">CD79B<\/jats:italic> Y196 mutations using droplet digital PCR in 55 patients with PSDLBCL, as well as the translocation of <jats:italic toggle=\"yes\">BCL2<\/jats:italic>\/<jats:italic toggle=\"yes\">BCL6<\/jats:italic>\/<jats:italic toggle=\"yes\">c-Myc<\/jats:italic> with FISH. We found mutations in <jats:italic toggle=\"yes\">MYD88<\/jats:italic> L265P (29\/55, 52.7%) and <jats:italic toggle=\"yes\">CD79B<\/jats:italic> Y196 (20\/55, 36.4%). The MCD-like subtype, defined by the mutation of <jats:italic toggle=\"yes\">MYD88<\/jats:italic> and\/or <jats:italic toggle=\"yes\">CD79B<\/jats:italic>, was found in 32 out of 55 cases (58.2%). This subtype largely consists of non-GCB type (31\/32, 96.9%; <jats:italic toggle=\"yes\">P<\/jats:italic>&lt;0.01) and double-expressor cases (20\/32, 62.5%; <jats:italic toggle=\"yes\">P<\/jats:italic>=0.01) compared with the <jats:italic toggle=\"yes\">MYD88<\/jats:italic>\/<jats:italic toggle=\"yes\">CD79B<\/jats:italic> co-wild type, with <jats:italic toggle=\"yes\">BCL6<\/jats:italic> translocation in a small subset (2\/32, 6.3%) and no translocations of <jats:italic toggle=\"yes\">BCL2<\/jats:italic> (0\/32) or <jats:italic toggle=\"yes\">c-Myc<\/jats:italic> (0\/32). The MCD-like subtype tended to relapse in specific sites such as the central nervous system, testis, and\/or skin compared with the co-wild type (<jats:italic toggle=\"yes\">P<\/jats:italic>=0.03), showing poorer outcomes in overall survival (<jats:italic toggle=\"yes\">P<\/jats:italic>=0.02) and progression-free survival (<jats:italic toggle=\"yes\">P<\/jats:italic>=0.01). In conclusion, our study highlights a high prevalence of <jats:italic toggle=\"yes\">MYD88<\/jats:italic> and <jats:italic toggle=\"yes\">CD79B<\/jats:italic> mutations in PSDLBCL, identifying an aggressive MCD-like subtype with a distinct relapse pattern. This molecular subclassification can be helpful for both prognostic prediction and therapeutic strategy in patients with PSDLBCL.<\/jats:p>","DOI":"10.1097\/pas.0000000000002329","type":"journal-article","created":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T09:00:27Z","timestamp":1730451627000},"page":"159-168","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["High Prevalence of MYD88 and CD79B Mutations in Primary Sinonasal Diffuse Large B-Cell Lymphoma"],"prefix":"10.1097","volume":"49","author":[{"given":"Fangli","family":"Peng","sequence":"first","affiliation":[{"name":"Pathology and Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3959-0813","authenticated-orcid":false,"given":"Takuro","family":"Igawa","sequence":"additional","affiliation":[{"name":"Pathology and Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Urata","sequence":"additional","affiliation":[{"name":"Department of Hematology and Blood Transfusion, Kochi Health Sciences Center, Kochi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Isoda","sequence":"additional","affiliation":[{"name":"Department of Pathology, Okayama Medical Center, Okayama"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sawako","family":"Ono","sequence":"additional","affiliation":[{"name":"Pathology and Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takehiro","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Pathology and Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Ennisshi","sequence":"additional","affiliation":[{"name":"Center for Comprehensive Genomic Medicine, Okayama University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinobu","family":"Maeda","sequence":"additional","affiliation":[{"name":"Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidetaka","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Pathology and Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,10,31]]},"reference":[{"key":"R2-20250115","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse large B-cell lymphoma","volume":"384","author":"Sehn","year":"2021","journal-title":"N Engl J Med"},{"key":"R3-20250115","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/hon.2968","article-title":"Sinonasal B-cell lymphomas: A nationwide cohort study, with an emphasis on the prognosis and the recurrence pattern of primary diffuse large B-cell lymphoma","volume":"40","author":"Eriksen","year":"2022","journal-title":"Hematol Oncol"},{"key":"R4-20250115","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"R5-20250115","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"key":"R6-20250115","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N Engl J Med"},{"key":"R7-20250115","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1084\/jem.194.12.1861","article-title":"Constitutive nuclear factor \u03baB activity is required for survival of activated B cell\u2013like diffuse large B cell lymphoma cells","volume":"194","author":"Davis","year":"2001","journal-title":"J. Exp. Med"},{"key":"R8-20250115","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma","volume":"463","author":"Davis","year":"2010","journal-title":"Nature"},{"key":"R9-20250115","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat Med"},{"key":"R10-20250115","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N Engl J Med"},{"key":"R11-20250115","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications","volume":"37","author":"Wright","year":"2020","journal-title":"Cancer Cell"},{"key":"R12-20250115","doi-asserted-by":"crossref","DOI":"10.1007\/s12185-024-03780-6","article-title":"Understanding the intrinsic biology of diffuse large B-cell lymphoma: recent advances and future prospects.","author":"Naoi","year":"2024","journal-title":"Int J Hematol"},{"key":"R13-20250115","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat Med"},{"key":"R14-20250115","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1182\/blood.2019003535","article-title":"Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report","volume":"135","author":"Lacy","year":"2020","journal-title":"Blood"},{"key":"R15-20250115","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/nan.12259","article-title":"Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas","volume":"42","author":"Nakamura","year":"2016","journal-title":"Neuropathol Appl Neurobiol"},{"key":"R16-20250115","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/leu.2013.348","article-title":"High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma","volume":"28","author":"Kraan","year":"2014","journal-title":"Leukemia"},{"key":"R17-20250115","first-page":"1598","article-title":"The molecular hallmarks of primary and secondary vitreoretinal lymphoma","volume":"6","author":"Bonzheim","year":"2022","journal-title":"Blood Adv"},{"key":"R18-20250115","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/ejh.13191","article-title":"CD79B mutations in primary vitreoretinal lymphoma: diagnostic and prognostic potential","volume":"102","author":"Yonese","year":"2019","journal-title":"Eur J Haematol"},{"key":"R19-20250115","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1016\/j.jid.2019.05.008","article-title":"Mutations of the B-Cell Receptor Pathway Confer Chemoresistance in Primary Cutaneous Diffuse Large B-Cell Lymphoma Leg Type","volume":"139","author":"Ducharme","year":"2019","journal-title":"JID"},{"key":"R20-20250115","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/PAS.0000000000000592","article-title":"Frequent MYD88 L265P and CD79B Mutations in Primary Breast Diffuse Large B-Cell Lymphoma","volume":"40","author":"Taniguchi","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"R21-20250115","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/PAS.0000000000001386","article-title":"Morphologic Patterns and the Correlation With MYD88 L265P, CD79B Mutations in Primary Adrenal Diffuse Large B-Cell Lymphoma","volume":"44","author":"Chen","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"R22-20250115","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1182\/blood-2017-12-822817","article-title":"High prevalence of MYD88 and CD79B mutations in intravascular large B-cell lymphoma","volume":"131","author":"Schrader","year":"2018","journal-title":"Blood"},{"key":"R23-20250115","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1038\/bcj.2013.28","article-title":"High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites","volume":"3","author":"Kraan","year":"2013","journal-title":"Blood Cancer J"},{"key":"R24-20250115","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2023020911","article-title":"Primary Large B-cell Lymphomas of Immune-Privileged Sites","author":"Roschewski","year":"2024","journal-title":"Blood"},{"key":"R25-20250115","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1182\/bloodadvances.2023011517","article-title":"Sinonasal DLBCL: molecular profiling identifies subtypes with distinctive prognosis and targetable genetic features","volume":"8","author":"Eriksen","year":"2024","journal-title":"Blood Adv"},{"key":"R26-20250115","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature09671","article-title":"Oncogenically active MYD88 mutations in human lymphoma","volume":"470","author":"Ngo","year":"2011","journal-title":"Nature"},{"key":"R27-20250115","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41586-018-0290-0","article-title":"A multiprotein supercomplex controlling oncogenic signalling in lymphoma","volume":"560","author":"Phelan","year":"2018","journal-title":"Nature"},{"key":"R28-20250115","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"key":"R29-20250115","first-page":"2196","article-title":"The impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHC","volume":"137","author":"Collinge","year":"2021","journal-title":"Blood"},{"key":"R30-20250115","doi-asserted-by":"crossref","first-page":"7116","DOI":"10.1002\/cam4.5512","article-title":"CD79B Y196 mutation is a potent predictive marker for favorable response to R-MPV in primary central nervous system lymphoma","volume":"12","author":"Yamaguchi","year":"2023","journal-title":"Cancer Med"},{"key":"R31-20250115","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1182\/blood-2018-99-114551","article-title":"Primary extranodal diffuse large B-cell lymphomas are enriched for mutations in MYD88 and CD79B","volume":"132","author":"Weissinger","year":"2018","journal-title":"Blood"},{"key":"R32-20250115","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1182\/blood-2015-10-673236","article-title":"Targetable genetic features of primary testicular and primary central nervous system lymphomas","volume":"127","author":"Chapuy","year":"2016","journal-title":"Blood"},{"key":"R33-20250115","doi-asserted-by":"crossref","first-page":"e1051","DOI":"10.1016\/j.clml.2022.08.006","article-title":"The prognostic significance of CD79B mutation in diffuse Large B-Cell Lymphoma: a Meta-analysis and Systematic Literature Review","volume":"22","author":"Xu","year":"2022","journal-title":"Clinical Lymphoma Myeloma and Leukemia"},{"key":"R34-20250115","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.ccell.2021.10.006","article-title":"Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL","volume":"39","author":"Wilson","year":"2021","journal-title":"Cancer Cell"},{"key":"R35-20250115","doi-asserted-by":"crossref","first-page":"e7005","DOI":"10.1002\/cam4.7005","article-title":"A single-centre, real-world study of BTK inhibitors for the initial treatment of MYD88mut\/CD79Bmut diffuse large B-cell lymphoma","volume":"13","author":"Deng","year":"2024","journal-title":"Cancer Med"},{"key":"R36-20250115","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ccell.2023.12.019","article-title":"Response to Bruton\u2019s tyrosine kinase inhibitors in aggressive lymphomas linked to chronic selective autophagy","volume":"42","author":"Phelan","year":"2024","journal-title":"Cancer Cell"},{"key":"R37-20250115","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid Neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"R38-20250115","doi-asserted-by":"crossref","first-page":"424","DOI":"10.3324\/haematol.2018.214122","article-title":"MYD88 mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis","volume":"105","author":"Joost","year":"2020","journal-title":"Haematologica"},{"key":"R39-20250115","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s11523-024-01057-w","article-title":"Deciphering the Prognostic Significance of MYD88 and CD79B Mutations in Diffuse Large B-Cell Lymphoma: Insights into Treatment Outcomes","volume":"19","author":"Xie","year":"2024","journal-title":"Targeted Oncology"},{"key":"R40-20250115","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1021\/ac403843j","article-title":"High Sensitivity Detection and Quantitation of DNA Copy Number and Single Nucleotide Variants with Single Color Droplet Digital PCR","volume":"86","author":"Miotke","year":"2014","journal-title":"Anal Chem"},{"key":"R41-20250115","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/hon.3073","article-title":"Clinical significance of MYD88 non-L265P mutations in diffuse large B-cell lymphoma","volume":"40","author":"Xie","year":"2022","journal-title":"Hematol Oncol"},{"key":"R42-20250115","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1158\/1078-0432.CCR-16-1922","article-title":"Biological and clinical relevance of associated genomic alterations in MYD88 L265P and non-L265P\u2013mutated diffuse large B-cell lymphoma: analysis of 361 cases","volume":"23","author":"Dubois","year":"2017","journal-title":"Clin Cancer Res"},{"key":"R43-20250115","doi-asserted-by":"crossref","first-page":"8483","DOI":"10.1007\/s00432-023-04714-1","article-title":"MYD88L265P and MYD88other variants show different molecular characteristics and prognostic significance in diffuse large B-cell lymphoma","volume":"149","author":"Qin","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"R44-20250115","doi-asserted-by":"crossref","first-page":"7459","DOI":"10.1182\/bloodadvances.2023010402","article-title":"Distribution and clinical impact of molecular subtypes with dark zone signature of DLBCL in a Japanese real-world study","volume":"7","author":"Urata","year":"2023","journal-title":"Blood Adv"},{"key":"R45-20250115","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.3390\/cancers13081785","article-title":"The incidence of Epstein-Barr virus-positive diffuse lB-cell lymphoma: a Systematic Review and Meta-Analysis","volume":"13","author":"Hwang","year":"2021","journal-title":"Cancers"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000002329","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T06:00:46Z","timestamp":1736920846000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000002329"}},"subtitle":["Identification of an MCD-like Subtype"],"short-title":[],"issued":{"date-parts":[[2024,10,31]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000002329","relation":{},"ISSN":["0147-5185","1532-0979"],"issn-type":[{"value":"0147-5185","type":"print"},{"value":"1532-0979","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,31]]}}}